Safe Antihistamines in Pregnancy: Loratadine, Cetirizine and Which to Avoid
TL;DR
- Allergic rhinitis affects up to 30% of women of childbearing age; untreated symptoms impair sleep, nutrition, and quality of life during pregnancy.
- Loratadine and cetirizine are the preferred antihistamines in pregnancy — both are second-generation, minimally sedating, and supported by reassuring human data.
- First-generation agents such as diphenhydramine and chlorpheniramine have longer track records but carry sedation and anticholinergic burdens.
- Avoid first-trimester use of brompheniramine and hydroxyzine where alternatives exist; never use pseudoephedrine-containing combination products in the first trimester.
- Always consult your prescriber before starting, stopping, or switching any medication during pregnancy or breastfeeding.
Why Allergies Matter in Pregnancy
Allergic rhinitis is the most common atopic condition encountered during pregnancy, with population-based surveys estimating prevalence between 20% and 30% among women of reproductive age (Wallace et al., J Allergy Clin Immunol 2008). Pregnancy itself modifies the immune landscape: a physiological shift toward T-helper-2 (Th2) dominance can worsen pre-existing allergic disease in roughly one-third of affected women, improve it in another third, and leave the remainder unchanged.
Antihistamines in pregnancy are among the most frequently requested over-the-counter medications, yet confusion persists about which agents are safe. The stakes are real — poorly controlled allergic rhinitis disrupts sleep, reduces oral intake (compounding nausea in early pregnancy), and may contribute to sinusitis or asthma exacerbations. At the same time, unnecessary fetal drug exposure must be minimized.
This article reviews the pharmacology, safety evidence, practical dosing, and breastfeeding considerations for the antihistamines most commonly used in pregnancy, grounded in guidance from the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), the U.S. Food and Drug Administration (FDA), and the National Library of Medicine's LactMed database.
How Antihistamines Work — A Brief Primer
Histamine, released primarily from mast cells, binds to H1 receptors on vascular endothelium, smooth muscle, and sensory nerve endings, producing the familiar triad of sneezing, rhinorrhea, and pruritus. H1-receptor antagonists — commonly called "antihistamines" — compete with histamine at these receptors, reducing symptom severity.
Antihistamines are classified by generation:
- First-generation (e.g., diphenhydramine, chlorpheniramine, hydroxyzine): cross the blood–brain barrier readily, causing sedation and anticholinergic effects (dry mouth, urinary retention, constipation). Short duration of action (4–6 hours).
- Second-generation (e.g., loratadine, cetirizine, fexofenadine): designed for peripheral selectivity, minimal CNS penetration, longer duration (12–24 hours), and fewer anticholinergic side effects.
During pregnancy, the clinical preference for second-generation agents is driven not only by a better side-effect profile but also by accumulating human safety data — particularly for loratadine and cetirizine.
Evidence-Based Safety: Which Antihistamines Are Preferred?
The former FDA letter-category system (A, B, C, D, X) was officially retired in 2015 under the Pregnancy and Lactation Labeling Rule (PLLR), but legacy categories remain widely referenced in clinical practice. The table below summarizes key agents.
Comparison Table — Antihistamine Safety in Pregnancy
| Antihistamine | Generation | Former FDA Category | Key Human Data | ACOG/Guideline Position |
|---|---|---|---|---|
| Loratadine (Claritin) | 2nd | B | Swedish Medical Birth Registry: >5,000 first-trimester exposures; no increased risk of major malformations (Källén, J Allergy Clin Immunol 2002) | Preferred first-line by ACOG Practice Bulletin and Joint Task Force on Practice Parameters |
| Cetirizine (Zyrtec) | 2nd | B | Prospective cohort (Einarson et al., Ann Allergy Asthma Immunol 1997): no excess malformations; Swedish registry data reassuring | Preferred first-line; ACOG-endorsed alternative to loratadine |
| Chlorpheniramine | 1st | B | Collaborative Perinatal Project: >1,000 exposures; long reassuring track record | Acceptable alternative when sedation is tolerable |
| Diphenhydramine (Benadryl) | 1st | B | Large datasets (>10,000 exposures in meta-analyses); generally reassuring, though some early studies raised concern for oral clefts — subsequent data did not confirm | Acceptable; widely used for nausea/insomnia in pregnancy, but sedation and anticholinergic effects limit routine use |
| Fexofenadine (Allegra) | 2nd | C | Limited human pregnancy data; animal studies showed decreased pup weight at high doses | Use only if loratadine/cetirizine insufficient; less preferred due to thinner evidence base |
| Hydroxyzine (Atarax, Vistaril) | 1st | C | Animal data showed cleft palate at high doses; human data limited but not reassuring in first trimester | Avoid in first trimester when possible; short courses later in pregnancy may be considered for severe pruritus |
| Brompheniramine | 1st | C | Some case–control data suggested possible association with malformations; inconsistent across studies | Avoid; better-studied alternatives exist |
| Desloratadine (Clarinex) | 2nd | C | Active metabolite of loratadine; limited direct pregnancy exposure data | Can be used if loratadine unavailable; extrapolation from parent compound provides some reassurance |
| Levocetirizine (Xyzal) | 2nd | B | Active enantiomer of cetirizine; less direct pregnancy data than cetirizine but mechanism identical | Reasonable alternative; extrapolation from cetirizine data |
Key takeaway: Loratadine and cetirizine remain the agents with the strongest combination of efficacy, tolerability, and human safety data in pregnancy. ACOG and the Joint Task Force on Practice Parameters both endorse them as first-line options.
Dosing and Practical Use in Pregnancy
Pharmacokinetic changes in pregnancy — increased plasma volume, higher renal clearance, and altered hepatic metabolism — can affect drug levels, but standard antihistamine doses are generally maintained.
Dosing Table — Common Antihistamines in Pregnancy
| Drug | Standard Adult Dose | Pregnancy-Specific Notes | Breastfeeding Compatibility (LactMed) |
|---|---|---|---|
| Loratadine | 10 mg once daily | No dose adjustment needed; take at same time daily for steady effect | Compatible — low levels in breast milk; no adverse effects reported in nursed infants |
| Cetirizine | 10 mg once daily (may split to 5 mg twice daily) | No dose adjustment; may cause mild drowsiness in some patients despite being second-generation | Compatible — small amounts excreted in milk; monitor infant for irritability or sedation |
| Chlorpheniramine | 4 mg every 4–6 hours (max 24 mg/day) | Use lowest effective dose; sedation may worsen pregnancy fatigue | Acceptable — may decrease milk supply at high doses per anecdotal reports; monitor infant for drowsiness |
| Diphenhydramine | 25–50 mg every 6–8 hours (max 300 mg/day) | Often used short-term for nausea (component of doxylamine–pyridoxine regimen context) or insomnia; avoid prolonged use due to anticholinergic load | Acceptable with caution — may reduce milk supply; can cause infant sedation or irritability |
| Fexofenadine | 180 mg once daily or 60 mg twice daily | Take on empty stomach with water (not fruit juice); limited pregnancy data warrants reserving as second-line | Probably compatible — limited lactation data; monitor infant |
Practical tips:
- Intranasal corticosteroids (budesonide is the preferred agent in pregnancy, per ACOG) should be considered first-line for moderate-to-severe allergic rhinitis, with oral antihistamines added if nasal symptoms are inadequately controlled.
- Nasal saline irrigation is safe and can reduce the need for pharmacotherapy.
- Combination products containing pseudoephedrine should be avoided in the first trimester due to a small but consistent association with gastroschisis and possibly other abdominal wall defects; after the first trimester, short courses may be cautiously considered for severe congestion under prescriber guidance.
- If a patient was well-controlled on loratadine or cetirizine before pregnancy, continuing the same agent is usually the simplest and safest strategy — switching mid-pregnancy introduces uncertainty without benefit.
Antihistamines for Nausea and Hyperemesis Gravidarum
First-generation antihistamines have an established role in managing nausea and vomiting of pregnancy (NVP). Their antiemetic effect is mediated through both H1-receptor and muscarinic-receptor blockade in the vomiting center.
- Doxylamine (an H1-antihistamine and the active component of Unisom SleepTabs in the U.S.) combined with pyridoxine (vitamin B6) is the only FDA-approved combination for NVP (marketed as Diclegis/Bonjesta). ACOG recommends this combination as first-line pharmacotherapy for NVP.
- Diphenhydramine 25–50 mg IV or IM is commonly administered in emergency settings for refractory hyperemesis gravidarum, often alongside ondansetron and intravenous fluids.
- Dimenhydrinate (Dramamine), a diphenhydramine salt, is used in some Canadian and European protocols for NVP, dosed at 50–100 mg every 4–6 hours.
These antiemetic uses are distinct from allergy management, but it is worth noting because pregnant patients may already be taking a first-generation antihistamine for nausea — adding a second antihistamine for allergy without accounting for this overlap could lead to excessive sedation or anticholinergic toxicity.
Side Effects and Monitoring
Common Side Effects by Generation
Second-generation (loratadine, cetirizine):
- Headache (3–5%)
- Mild drowsiness — more common with cetirizine than loratadine
- Dry mouth (uncommon at standard doses)
- Fatigue
First-generation (diphenhydramine, chlorpheniramine):
- Significant sedation and psychomotor impairment
- Dry mouth, blurred vision, urinary retention, constipation (anticholinergic effects)
- Paradoxical excitability (rare)
Monitoring Considerations in Pregnancy
- Sedation risk: Particularly relevant in late pregnancy, when fatigue is already pronounced. Sedating antihistamines may increase fall risk.
- Neonatal effects: High-dose or prolonged first-generation antihistamine use near delivery has been associated with transient neonatal irritability, tremors, and feeding difficulties — likely due to anticholinergic withdrawal. This is uncommon at standard doses but warrants awareness.
- Oxytocin interaction: Diphenhydramine at very high intravenous doses can inhibit uterine contractions in animal models; this is not clinically significant at therapeutic human doses, but the theoretical concern is occasionally raised in labor and delivery contexts.
- No routine laboratory monitoring is required for oral antihistamine use at standard doses.
Contraindications, Interactions, and Agents to Avoid
Contraindications
| Scenario | Recommendation |
|---|---|
| Known hypersensitivity to the specific antihistamine or its excipients | Absolute contraindication — switch to a structurally unrelated agent |
| Severe hepatic impairment | Reduce dose of loratadine (hepatically metabolized); cetirizine (renally cleared) may be preferred |
| Concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) | Monitor for increased loratadine levels; clinical significance at OTC doses is low |
| Combination with other CNS depressants (opioids, benzodiazepines) | Avoid first-generation antihistamines or use with extreme caution — additive sedation |
| Narrow-angle glaucoma | Avoid first-generation agents (anticholinergic mydriasis may precipitate angle closure) |
| Urinary retention / symptomatic prostatic hypertrophy | Avoid first-generation agents |
Agents to Avoid or Use with Caution in Pregnancy
- Hydroxyzine: Former FDA category C. Animal teratogenicity at high doses (cleft palate in mice). Human data are sparse. Avoid in the first trimester; if needed later for severe pruritus (e.g., intrahepatic cholestasis of pregnancy–related itch), use the lowest effective dose for the shortest duration.
- Brompheniramine: Some case–control data raise concern; better alternatives exist.
- Pseudoephedrine-antihistamine combinations: Pseudoephedrine is the primary concern — associated with gastroschisis risk in first-trimester exposure. Avoid combination products (e.g., loratadine-D, cetirizine-D) in the first trimester entirely.
- Phenylephrine-antihistamine combinations: Phenylephrine's vasoconstrictor properties raise theoretical concerns for uterine blood flow, though evidence is limited. Avoid when possible.
Special Populations
Breastfeeding Transition
For women well-controlled on loratadine or cetirizine during pregnancy, continuing the same agent through breastfeeding is appropriate. LactMed data confirm:
- Loratadine pregnancy use can transition directly into breastfeeding: infant doses via milk are estimated at <1% of the maternal weight-adjusted dose. No adverse effects reported in published lactation studies.
- Cetirizine pregnancy use similarly transitions well: excreted in milk in small amounts. The infant receives an estimated 0.3–0.6% of the maternal dose. Theoretical concern for mild infant sedation exists but is rarely reported.
- First-generation agents (diphenhydramine, chlorpheniramine) are generally acceptable during breastfeeding but may reduce milk supply — a concern particularly in the early postpartum period when lactation is being established. The American Academy of Pediatrics (AAP) does not list these agents as contraindicated during breastfeeding but advises monitoring the infant for drowsiness and feeding difficulty.
If starting a new antihistamine while breastfeeding, loratadine or cetirizine is preferred over first-generation agents due to lower milk transfer and minimal infant sedation.
Asthma Comorbidity
Up to 20% of pregnant women with allergic rhinitis also have asthma. Poorly controlled rhinitis can worsen asthma symptoms. An integrated approach — intranasal budesonide plus oral loratadine or cetirizine, combined with inhaled corticosteroids for asthma — is consistent with ACOG and National Asthma Education and Prevention Program (NAEPP) recommendations.
Chronic Urticaria
Chronic spontaneous urticaria may flare during pregnancy. Second-generation antihistamines at standard dose are first-line. Updosing (e.g., cetirizine 20 mg/day) is practiced in non-pregnant populations per EAACI/GA²LEN guidelines, but data in pregnancy are limited — discuss with the patient's allergist before exceeding standard doses.
Allergic Rhinitis Management Algorithm in Pregnancy
Step 1 — Non-pharmacological measures: Allergen avoidance, nasal saline irrigation, environmental controls (HEPA filters, bedding encasements for dust mite allergy).
Step 2 — Monotherapy: Intranasal corticosteroid (budesonide preferred) or oral second-generation antihistamine (loratadine or cetirizine).
Step 3 — Combination therapy: Intranasal budesonide plus oral loratadine or cetirizine if monotherapy is insufficient.
Step 4 — Add-on options: Intranasal cromolyn sodium (safe in pregnancy, limited efficacy). Short-course intranasal decongestant (oxymetazoline ≤3 days) for severe obstruction — avoid oral decongestants in the first trimester.
Step 5 — Specialist referral: If symptoms remain uncontrolled, refer to an allergist. Allergen immunotherapy that was initiated before pregnancy may be continued at maintenance dose but should not be started de novo during pregnancy (risk of anaphylaxis).
Red Flags — When to Seek Immediate Medical Care
Seek urgent medical attention if you experience any of the following while taking antihistamines during pregnancy:
- Signs of anaphylaxis: sudden onset of swelling (lips, tongue, throat), difficulty breathing, widespread hives, dizziness, or collapse — call emergency services immediately.
- Severe drowsiness or confusion after taking a first-generation antihistamine — especially if combined with other sedating medications.
- Inability to keep fluids down for more than 12 hours during pregnancy, whether or not related to allergy treatment — this may indicate hyperemesis gravidarum requiring intravenous hydration.
- New-onset wheezing or chest tightness — may indicate asthma exacerbation rather than simple allergic rhinitis.
- Severe itching with dark urine, pale stools, or right upper quadrant pain — this constellation may suggest intrahepatic cholestasis of pregnancy, which requires specific evaluation (serum bile acids) and is not simply "allergies."
- Decreased fetal movement in the third trimester — while not directly related to antihistamines, any perceived change in fetal activity warrants prompt evaluation.
Frequently Asked Questions
Q: Is loratadine safe in the first trimester of pregnancy? A: Yes, loratadine is considered one of the safest antihistamines for use throughout pregnancy, including the first trimester. The Swedish Medical Birth Registry study involving over 5,000 first-trimester exposures found no increased risk of major malformations. Both ACOG and the Joint Task Force on Practice Parameters endorse it as a first-line option.
Q: Can I take cetirizine while pregnant? A: Cetirizine is endorsed alongside loratadine as a preferred antihistamine during pregnancy. Prospective studies have not demonstrated an increased risk of birth defects. Some women find cetirizine slightly more sedating than loratadine — if this is problematic, switching to loratadine is reasonable.
Q: Is diphenhydramine (Benadryl) safe during pregnancy? A: Diphenhydramine has a long track record of use in pregnancy with generally reassuring safety data. It is commonly used for nausea, insomnia, and acute allergic reactions. However, its sedating and anticholinergic properties make it less suitable for daily allergy management. For ongoing allergic rhinitis, a second-generation antihistamine is preferred.
Q: Can antihistamines cause birth defects? A: The second-generation antihistamines loratadine and cetirizine have not been associated with an increased risk of birth defects in large epidemiologic studies. Some older first-generation agents (brompheniramine, hydroxyzine) have raised concerns in isolated studies, which is why they are not recommended as first-line options. No antihistamine carries an FDA category D or X designation.
Q: Which allergy medications should I avoid during pregnancy? A: Avoid combination products containing pseudoephedrine in the first trimester. Avoid hydroxyzine and brompheniramine when safer alternatives (loratadine, cetirizine) are available. Do not initiate allergen immunotherapy during pregnancy. Always check with your pharmacist or prescriber before taking any over-the-counter allergy product, as many contain multiple active ingredients.
Q: Can I breastfeed while taking antihistamines? A: Yes. Loratadine and cetirizine are the preferred choices during breastfeeding, with minimal transfer into breast milk and no reported adverse infant effects. First-generation antihistamines are not contraindicated but may cause infant sedation and could theoretically reduce milk supply. LactMed is an excellent free resource for checking individual drug compatibility with breastfeeding.
Q: What about nasal sprays — are they safer than pills? A: Intranasal corticosteroids (budesonide is preferred in pregnancy) deliver medication locally with very low systemic absorption, making them an excellent option. They can be used alone or alongside oral antihistamines. Intranasal antihistamines (e.g., azelastine) have limited pregnancy data and are not first-line.
Q: I was taking fexofenadine before I became pregnant. Should I switch? A: Fexofenadine has less human pregnancy safety data than loratadine or cetirizine (former FDA category C versus B). Most guidelines recommend switching to loratadine or cetirizine during pregnancy. Discuss the transition with your prescriber — both alternatives are taken once daily and provide comparable efficacy for allergic rhinitis.
References
-
ACOG Practice Bulletin No. 211: Critical Care in Pregnancy. Obstetrics & Gynecology 2019;133(5):e303–e319. (General principles of medication use in pregnancy; antihistamine recommendations referenced in ACOG clinical guidance documents.)
-
Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Allergy Clin Immunol 2002;110(1):7–12. PMID: 12110808.
-
Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997;78(2):183–186. PMID: 9048526.
-
Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol 1997;14(3):119–124. PMID: 9259911.
-
Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122(2 Suppl):S1–S84. PMID: 18662584.
-
Drugs and Lactation Database (LactMed). National Library of Medicine. Available at: toxnet.nlm.nih.gov. Accessed 2026.
-
So M, Bozzo P, Inoue M, Einarson A. Safety of antihistamines during pregnancy and lactation. Can Fam Physician 2010;56(5):427–429. PMID: 20463270.
-
Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 2002;65(6):250–253. PMID: 12007530.
-
NICE Clinical Knowledge Summaries: Allergic rhinitis. Last revised 2023. Available at: cks.nice.org.uk.
-
Namazy JA, Schatz M. The treatment of allergic respiratory disease during pregnancy. J Investig Allergol Clin Immunol 2016;26(1):1–7. PMID: 27012011.
-
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022;77(3):734–766. PMID: 34536239.
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience in medication safety, pharmacotherapy optimization, and patient education. He has worked across hospital, community, and consulting pharmacy settings with particular interest in maternal–fetal pharmacology and evidence-based prescribing. Dr. Ozarchuk writes for PillsCard.com to bridge the gap between clinical pharmacy literature and the information patients and caregivers need to make informed decisions about their medications.
Medical Disclaimer
The information provided in this article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for professional medical judgment. Always consult a qualified healthcare provider — such as your obstetrician, midwife, or pharmacist — before starting, changing, or stopping any medication during pregnancy or breastfeeding. Individual circumstances vary, and treatment decisions should be made in partnership with your care team. PillsCard.com and the author assume no liability for actions taken based on this content.